Based on the individual costs of screening tests for Hepatitis B (£6.30) and C (£5.13), for the 1115 current TB patients, our trust wide hepatitis screening costs were estimated at £12,744. The approximate cost of a liver transplant operation at Kings College Hospital in 2012 was £125,000, not including the additional after care costs and accounting for possible complications. We feel the cost of hepatitis screening is outweighed by the benefits of identifying patients with positive serology in a timely fashion; permitting closer monitoring of their liver function and initiating an early gastroenterology referral.

It is vital we attempt to reduce the morbidity and possible mortality of hepatotoxicity in hepatitis positive TB patients; the financial, emotional and psychological implications for a patient undergoing a liver transplant are enormous. We propose that hepatitis screening is incorporated into current TB guidelines.

P95 WHY HAVE TB NOTIFICATIONS DECREASED BY 50% IN FOUR YEARS, IN A RURAL DISTRICT OF ZIMBABWE?

¹HE Patrick, ²E Manomano, ²S Sah, ³N Kwenzakwenkosi, ³C Mushore, ⁴RD Barker; ¹National Institute for Health and Clinical Excellence, London, UK; ²TB Alert, Brighton, UK; ³Department of Health and Child Welfare, Manicaland Province, Zimbabwe; ⁴King's Health Partners, London, UK

10.1136/thoraxjnl-2013-204457.245

Introduction Annual TB notifications in Buhera District, Manicaland, peaked at 1,665 in 2008 and fell to 866 in 2012. The fall in TB notifications is disproportionate to national trends.¹ We considered three possible reasons for the fall in TB incidence; a real reduction related to improved health of the population, an apparent reduction due to failure to identify or register new cases, and an apparent reduction due to fewer patients coming from outside the district to use relatively high quality services. We analysed existing data and planned further exploration.

Methods We used the district's electronic TB database maintained by the charity TB Alert. We also accessed data relating to a recent pilot of the use of GeneXpert in the District. We planned further analyses to explore within district variation in notifications. We planned interviews with TB coordinators, primary care, hospital staff and senior staff from within and outside the province.

Results The district TB register appeared complete. Treatment success rates increased from 2006 (55%) but stabilised at 65–70%. The proportion of TB patients who died peaked at 20% in 2006 and reduced to 10.5% in 2011 possibly due to changes in case ascertainment. Re-treatment cases increased from 2% in 2007 to 8.5% in 2012. Use of the GeneXpert machine identified 1 case of multi-drug resistant TB in 2008, increasing to 29 cases in 2012. The proportion of TB patients coming from outside the district seeking services appears to be constant, but high, at 22% in 2008 and 23% in 2012.

Conclusions Initial analyses suggest that TB documentation in the district is well maintained.² However there are significant changes in the local epidemiology of TB and the dramatic fall in the local incidence of tuberculosis is not completely explained. Further exploration of local TB documentation and practice associated with consultation with national and international TB experts should help to clarify the situation.

REFERENCES

1. World Health Organisation. Global Tuberculosis Report, 2012. http://www.who.int/tb/publications/global_report/gtbr12_annex2.pdf

2. Scott KM, Millard FJC, Smith RM, Manomano E, Glenshaw M, Barker RD. Five years of support for a tuberculosis programme in rural Zimbabwe: What has been achieved? *Thorax* 2009;64 (Suppl IV):A11.

P96 CHARACTERISTICS AND OUTCOMES OF MULTI-DRUG RESISTANT TUBERCULOSIS PATIENTS IN A MAJOR URBAN CENTRE IN THE UK

¹GC Hagan, ²F Edwards, ¹J Nation, ³H Kunst, ³M Dedicoat, ¹N Nathani; ¹City Hospital, Birmingham, United Kingdom; ²Medical School, University of Birmingham, Birmingham, United Kingdom; ³Birmingham Chest Clinic, Heart of England NHS Foundation Trust, Birmingham, United Kingdom

10.1136/thoraxjnl-2013-204457.246

Introduction and objectives Multi-drug resistant tuberculosis (MDR-TB), defined as TB resistant to rifampicin and isoniazid is an expanding problem. 1.6% of TB isolates in the UK are MDR-TB, but rates are higher in some parts of the world. Treatment is usually 20–24 months and frequently associated with significant side effects. In our city, MDR-TB is mostly managed in two main hospitals. We sought to examine the characteristics and outcomes of our MDR-TB patients. **Methods**

Patients from 1st Jan 2008 from one institution and 1st Jan 2009 from the other institution were included with a cutoff period of 1st May 2013 and follow up to 1st June 2013. Data was gathered from case note review and enhanced tuberculosis surveillance data.

Results 31 patients were identified; demographics are shown in table 1. Site of TB was pulmonary in 18(58%) patients, lymph node in 10(32%), soft tissue in 2(6%), and intra-cerebral in 1 (3%). 10(32%) patients were on standard anti TB treatment at time of diagnosis. 22(71%) patients developed side effects of treatment; these included ototoxicity (7 patients), gastrointestinal side effects (4 patients), hypothyroidism due to para-aminosalicylic acid or prothionamide (2 patients) and neuropsychiatric side effects from cycloserine (2 patients). 9(29%) patients underwent a surgical procedure; 7 for diagnosis and 2 to assist treatment (both lobectomies). Treatment was ongoing in 14(45%) patients and 11(35%) patients had completed treatment by the cutoff period. 4(12%) patients defaulted and 2 patients were transferred out during treatment (1 overseas, 1 to another UK centre).

Conclusions The lack of MDR-TB risk factors in a proportion of patients underscores the importance of trying to obtain microbiological samples and utilisation of resistance mutation analysis. Side effects are frequent and treatment should be undertaken by physicians with expertise. The BTS MDR-TB service plays a valuable role in management of these complex patients.

Abstract P96 Table 1.

No. Male	22 (67%)
Mean age (Median +/- IQR years)	29 (+/- 11)
UK Born	6 (19%)
Born in South Asia/Former USSR/Sub-Saharan Africa	14 (45%)/6 (19%)/5 (16%)
Time in prison	4 (13%)
HIV +ve	2 (6%)
Extensively drug resistant tuberculosis	3 (9%)
Previous or current TB treatment at diagnosis	11 (35%)
MDR-TB Contact	6 (19%)
Homelessness	2 (6%)
Renal disease	2 (6%)